Renalys Pharma begins patient dosing in registrational phase III trial of sparsentan for IgA nephropathy in Japan
Renalys Pharma, Inc. announced today that the first person was dosed in its registrational phase III clinical trial of sparsentan for the treatment of IgA nephropathy in Japan. In April this year Renalys submitted an Investigational New Drug (IND) …